Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Total Current Liabilities (2016 - 2025)

Purple Biotech has reported Total Current Liabilities over the past 7 years, most recently at $7.1 million for Q4 2022.

  • Quarterly Total Current Liabilities rose 66.07% to $7.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2022, up 66.07% year-over-year, with the annual reading at $7.1 million for FY2022, 66.07% up from the prior year.
  • Total Current Liabilities was $7.1 million for Q4 2022 at Purple Biotech, up from $5.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $29.4 million in Q2 2020 and troughed at $3.1 million in Q4 2020.
  • The 5-year median for Total Current Liabilities is $5.4 million (2019), against an average of $6.8 million.
  • Year-over-year, Total Current Liabilities skyrocketed 516.51% in 2018 and then tumbled 88.1% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $3.3 million in 2018, then grew by 7.0% to $3.5 million in 2019, then dropped by 12.63% to $3.1 million in 2020, then skyrocketed by 37.19% to $4.2 million in 2021, then soared by 66.07% to $7.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Total Current Liabilities are $7.1 million (Q4 2022), $5.9 million (Q3 2022), and $5.4 million (Q2 2022).